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The Beta-Blocker Heart Attack Trial was a placebo•
controlled, randomized, double-blind clinical trial of the 
long-term administration of propranolol hydrochloride 
to patients who had had at least one myocardial infarc•
tion. Among 3,837 patients followed up for an average 
of 25 months, 3,290 (85.7%) had 24 hour ambulatory 
electrocardiograms performed at the baseline exami•
nation. Four classifications of arrhythmia were exam•
ined. One of these, the presence of complex ventricular 
arrhythmias (at least 10 ventricular premature beats/h, 
or at least one pair or run of ventricular premature beats 
or multiform ventricular premature beats) was the 
subgroup of major interest. Regardless of the classifi•
cation, the presence of arrhythmia identifies a group of 
patients with a higher risk of total mortality, coronary 
heart disease mortality, sudden cardiac death and in•
stantaneous cardiac death. 
Propranolol and other beta-receptor blocking agents have 
been shown in clinical trials to decrease mortality (1-3) and 
reduce ventricular premature beat frequency (4-6) in pa•
tients who have had myocardial infarction. Prospective ep•
idemiologic studies (7-11) found relations between the pres•
ence of ventricular premature beats and increased mortality 
in such patients. One might, therefore, expect propranolol 
to be especially effective in patients with myocardial in•
farction and ventricular premature beats. 
The Beta-Blocker Heart Attack Trial was a placebo-con•
trolled, randomized, double-blind clinical trial of the long•
term administration of propranolol in patients who had had 
at least one documented myocardial infarction. A total of 
3,837 patients in 31 centers were assigned to two groups 
(1,916 patients to propranolol, 180 or 240 mg/day, and 
1,921 patients to matching placebo) and followed up for an 
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The a priori subgroup hypothesis that sudden death 
would be preferentially reduced by prppranolol in pa•
tients with complex ventricular arrhythmias was not 
supported. The relative benefit of propranolol in reduc•
ing sudden death for this subgroup was 28 versus 16% 
for the subgroup without ventricular arrhythmia (rel•
ative risk of 0.72 versus 0.84, a nonsignificant relative 
difference of 14%). There were similar findings for two 
of the three other classifications of arrhythmia and for 
the other response variables. Although propranolol does 
not appear to be of special relative benefit in patients 
with ventricular arrhythmia, the presence of the ar•
rhythmia does identify a high-risk group. The mecha•
nism by which propranolol reduces mortality is still un•
clear, but is probably not solely an antiarrhythmic one. 
(J Am Coil CardioI1986;7:1-8) 
average of 25 months. A previous publication by the Beta•
Blocker Heart Attack Trial (1) reported a 26% reduction of 
total mortality in patients with previous myocardial infarc•
tion assigned to propranolol therapy as compared with sim•
ilar patients assigned to a placebo. Cause-specific mortality 
analyses indicated that both sudden and nonsudden coronary 
heart disease mortality were decreased in the propranolol 
group. A second paper by the Beta-Blocker Heart Attack 
Trial research group (12) reported on coronary event inci•
dence (coronary heart disease mortality plus nonfatal myo•
cardial infarction) and nonfatal events. Coronary event in•
cidence was 23% lower in the propranolol-treated group and 
nonfatal reinfarction was 16% lower. 
This report considers the effect of propranolol therapy 
on coronary deaths in patients with ventricular arrhythmias 
at the time of enrollment, as determined by means of 24 
hour ambulatory electrocardiograms. One of the protocol•
specified subgroup hypotheses of the Beta-Blocker Heart 
Attack Trial was that propranolol would be particularly ef•
fective in reducing sudden cardiac death (that is, death within 
1 hour of onset of symptoms) in patients with complex 
ventricular premature beats. Other end points (total mor•
tality, coronary heart disease mortality and instantaneous 
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cardiac death) and adverse effects, as well as other classi•
fications of ventricular arrhythmia, are also examined. 
Methods 
Study design. Recruitment for study participants began 
on June 19, 1978 and ended on October 2, 1980. Men and 
women aged 30 to 69 years who were hospitalized with 
symptoms and electrocardiographic and enzymatic changes 
compatible with an acute myocardial infarction were can•
didates for enrollment in the trial. Reasons for exclusion 
from the study included medical contraindications to pro•
pranolol, life-threatening illness other than coronary heart 
disease and the use of beta-receptor blocking drugs by the 
patient. Informed consent was obtained from all patients in 
the study. They were enrolled 5 to 21 days after hospital 
admission, while they were still hospitalized. Follow-up 
visits were scheduled at 1 month, 6 weeks and 3 months 
after randomization, and at subsequent 3 month intervals. 
A detailed description of the Beta-Blocker Heart Attack 
Trial design and methods has been reported elsewhere (13). 
Holter monitoring. Ambulatory electrocardiographic 
monitoring was encouraged at baseline, but was not man•
datory for patient enrollment. At the 6 week visit, a second 
24 hour ambulatory electrocardiogram was performed on 
840 randomly selected patients representing approximately 
25% of the number performed at bas!:!line. 
The 24 hour, two channel, reel to reel Holter magnetic 
tapes were generated on Avionics model No. 445 recorders 
and processed by the CardioData system which is digital, 
software-based (the Worcester Polytechnic Institute algo•
rithm) (14) and capable of differentiating up to 25 different 
electrocardiographic variables involving rate and rhythm 
change. As electrocardiogram complexes are noted by the 
computer, an operator verifies the decision, thus providing 
human interaction with the computer. The CardioData sys•
tem analysis method has been validated (14) both for ac•
curacy and precision for ventricular premature beat detec•
tion. A quality control program involved the blinded analysis 
of several nand-counted tapes and reanalysis of selected 
Beta-Blocker Heart Attack Trial tapes. 
Arrhythmia definitions. The patient subgroup of major 
interest, as specified in the protocol, had complex ventric•
ular premature beats defined as the presence of one or more 
of the following features on the 24 hour electrocardiogram 
recordings: multiform ventricular premature beats, an av•
erage of at least 10 ventricular premature beats/h on the 24 
hour recording or at least one pair or run of ventricular 
premature beats. Multiform ventricular premature beats were 
defined as beats with varying configuration, in either chan•
nel, noted visually by the scanning technician and confirmed 
by the supervising cardiologist. 
Because ventricular ectopic activity is categorized by 
differing criteria in other reports, three other patient subgroups 
are also cqnsidered in this report. These are: 1) patients with 
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at least one ventricular premature beat during the monitoring 
period; 2) patients with an average of at least 10 ventricular 
premature beats/h; and 3) patients with an average of at least 
10 ventricular premature beats/h plus at least one pair or 
run of ventricular premature beats plus multiform ventricular 
premature beats. 
Statistics. In making comparisons between the two 
groups, the risk of having a cardiac event in the propranolol•
treated group relative to the placebo-treated group (relative 
risk) was calculated. A relative risk of less than 1 indicates 
a lower observed incidence of the specified events in the 
propranolol-treated group. When many subgroup compar•
isons are made, interpretation of statistical significance is 
difficult because there is an increased probability of ob•
serving p values below an arbitrary significance level by 
chance alone. In addition, the small sample sizes in the 
subgroups result in a reduced statistical power for detecting 
true relative differences. Therefore, a test of significance 
was performed only for the specified end point of sudden 
coronary heart disease death in the Beta-Blocker Heart At•
tack Trial subgroup with complex ventricular premature beats, 
as defined in the protocol. Sudden death was defined as 
death from coronary heart disease, occurring less than 1 
pour after the onset of symptoms. Instantaneous death, a 
subset of sudden death, was defined as death occurring 
abruptly, without symptoms. 
Results 
Baseline findings. Ambulatory electrocardiograms were 
performed at the baseline examination in 86.1 % (1,650 of 
1916) of those randomized to propranolol and 85.4% (1,640 
of 1,921) of those randomized to placebo. Examination of 
the baseline characteristics of those with and without am•
bulatory electrocardiogram showed excellent agreement in 
most respects. Slightly more patients with ambulatory elec•
trocardiograms had a history of angina (36.8 to 32.4%) and 
ST elevation on the electrocardiogram at rest (13.8 to 10.6%), 
whereas fewer patients with ambulatory electrocardiograms 
had T wave abnormalities on the electrocardiogram at rest 
(64.5 to 71.8%) and were using an antiarrhythmic drug in 
the hospital before randomization (45.2 to 50.5%). 
Table 1 shows baseline variables for the patients with 
the four classifications of ventricular arrhythmia, both treat•
ment groups combined. In general, variables associated with 
increasing risk of mortality, such as age, history of prior 
myocardial infarction, presence of congestive heart failure, 
cardiomegaly and use of antiarrhythmic agents, diuretic agents 
and digitalis, were more common in patients meeting more 
stringent classifications of arrhythmia. For all four arrhyth•
mia classifications, there was excellent baseline compara•
bility between the propranolol and placebo-treated groups. 
Mortality. Total mortality and cause-specific mortality, 
by treatment assignment, are shown in Table 2 for the four 
classifications of ventricular arrhythmia and for the patients 
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Table 1. Baseline Variables for Patients With Ventricular Arrhythmia 
VPBs 2" 10/h or VPBs 2" IO/h Plus 
VPB~ > 0 Runs or Multlform* VPBs 2" 10/h Runs Plus Multifonn 
Vanable (n = 2.750) (n = 1.338) (n = 435) (n = 234) 
Male (%) 840 835 81.1 83.3 
Mean age (yr) 55.3 565 57.4 58.6 
Mean SBP (mm Hg) 112.0 112.9 1134 114.5 
Mean DBP (mm Hg) 72.4 72.7 73.1 74.0 
Mean HR (beats/mm) 759 76.0 76.4 769 
Current smoker (%) 579 54.1I 52.0 52 I 
Medical hl~tory (0/() 
Prior MI 14.4 194 27.1 37.2 
Angma pectons 374 398 42.3 46.6 
CHF 9.8 12.0 14.5 15.8 
Takmg beta-blocker 74 95 11.7 137 
before MI 
In-hospital events (%) 
CHF 15.1 17.3 20.9 21.4 
Ventncular tachycardia 236 25.8 22.5 244 
Use of antiarrhythmic drug 46.2 48.6 53.8 534 
Drugs bemg used at time 
of randomization (%) 
Antiarrhythmic agents 17.9 20.6 306 31 2 
Diuretic drugs 17.9 200 24.4 286 
Digitalis 139 16.1 20.5 25.6 
LocatIOn of BHAT MI (%) 
Anterior 27.1 273 28.5 30.8 
Anterior/mfenor 100 12.3 14.5 15.4 
Infenor 31.7 30.8 278 252 
Nontransmural 227 21 7 21.1 20.1 
Non-BHAT MI 85 79 8.0 8.5 
Abnonnalitles at rest ECG (%) 
Q-QS waves 674 66.9 656 64.9 
ST depre5slon 280 3\.1 306 35.1 
ST elevation 13.5 12.9 11.8 132 
T wave abnonnality 65.8 68.9 664 70.2 
Ventncular 93 10.3 11.5 12.3 
conduction defect 
Cardiomegaly (%) 36.0 38.3 40.2 46.2 
Median time from MI to 93 96 9.7 9.5 
enrollment (days) 
*Protocol definition. BHAT = Beta-Blocker Heart Attack Trial; CHF = congestive heart failure; DBP = 
diastolic blood pressure; ECG = electrocardiogram; HR = heart rate; MI = myocardial infarctIOn; Non-BHAT 
MI = c1imcal myocardial mfarction not meeting Beta-Blocker Heart Attack Trial definitIOn; SBP = systolic 
blood pressure; VPB = ventricular premature beat 
without arrhythmia. In general, the placebo-treated patients 
having more stringent classifications of arrhythmia had higher 
event rates. Total mortality for patients with increasing grades 
of arrhythmias went from 10.9 to 15.2 to 19.9 to 19.6%, 
respectively. Sudden death, which accounts for about half 
of total mortality, increased from 5. 1 to 7.7 to 9.0 to 10.7 % , 
respectively. The other outcomes showed similar trends. 
Regardless of the classification of arrhythmia, total and 
cause-specific mortality were higher among those patients 
with arrhythmia than among those without. Thus, for the 
patients with at least one ventricular premature beat, total 
mortality was 7.9 and 10.9% in the propranolol- and pla•
cebo-treated groups, respectively. Among patients with no 
recorded ventricular premature beats, the mortality rate of 
the propranolol-treated group was 3.2% versus 5.0% for the 
placebo-treated group. Comparisons for other end point!> 
and classifications of arrhythmia show the same relations. 
In all except one case, the frequencies of events in the 
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Table 2. Outcome by Classification of Arrhythmia According to Treatment Group 
Classification of 
Arrhythmia 
VPB > 0 
Present 
Propranolol 
Placebo 
Absent 
Propranolol 
Placebo 
n 
1,370 
1,380 
280 
260 
Total 
Mortality 
(%) 
7.9J 
10.9 
3.2J 
5.0 
VPB 2: IO/h or runs or multiform VPB* 
Present 
Propranolol 
Placebo 
Absent 
Propranolol 
Placebo 
VPB 2: IO/h 
Present 
Propranolol 
Placebo 
Absent 
Propranolol 
Placebo 
672 
666 
978 
974 
224 
211 
1,426 
1,429 
IO.4J 
15.2 
12.9J 
19.9 
6.2J 
8.5 
VPB 2: IO/h plus runs plus multiform VPB 
Present 
Propranolol 
Placebo 
Absent 
Propranolol 
Placebo 
122 
112 
1,528 
1,528 
18.9J 
19.6 
6.2J 
9.2 
Relative 
Risk 
0.73 
0.64 
0.69 
0.75 
0.65 
0.73 
0.96 
0.67 
CHD 
Mortality 
(%) 
6.8J 
9.6 
2.9J 
3.8 
9.1 J 
13.5 
4.1 J 
5.3 
10.7 
17.1...1 
15.6J 
17.9 
Relative 
Risk 
0.71 
0.74 
0.67 
0.77 
0.63 
0.73 
0.87 
0.67 
Sudden 
Death 
(%) 
4.0J 
5.1 
5.5J 
7.7 
2.IJ 
2.6 
7.6J 
9.0 
2.9J 
4.0 
1O.7J 
10.7 
2.9J 
4.2 
Relative 
Risk 
0.79 
0.46 
0.72 
0.84 
0.84 
0.72 
0.99 
0.70 
Instantaneous 
Death 
(%) 
2.6J 
3.7 
3.6J 
5.7 
5.8J 
7.6 
1.8J 
2.7 
9.8J 
8.9 
Relative 
Risk 
0.71 
0.70 
0.63 
0.88 
0.77 
0.67 
1.10 
0.60 
*Protocol definition. CHD = coronary heart disease; VPB = ventricular premature beat. 
propranolol-treated group were less than those in the com•
parable placebo-treated group (relative risk < 1). 
Table 2 also compares the relative risks (propranolol 
versus placebo) of the various outcomes in the four defined 
subgroups with the relative risks in the complementary groups. 
In many of the cases, the relative risks in the patients with 
arrhythmias were similar to those in the patients without 
arrhythmias. The major exception is the group meeting the 
most stringent classification of arrhythmia. Although there 
were only a few patients with this classification, the relative 
risks were uniformly greater than those in the patients with•
out this arrhythmia. 
The a priori subgroup hypothesis that sudden death would 
be preferentially reduced in patients with complex ventric•
ular arrhythmias was not supported. The relative risk of 
sudden death for this subgroup was 0.72 versus 0.84 for 
the subgroup without ventricular arrhythmia, a 14% relative 
difference. The value of the Mantel-Haenszel chi-square 
analysis of homogeneity was 0.20 (l df), indicating that 
there is no statistical evidence of a difference between 
these results (p > 0.05). Using the other classifications of 
arrhythmia, no preferential effect of propranolol on sudden 
death was observed. 
Concomitant therapy and compliance. The percent•
ages of patients withdrawn from the study medication be•
cause of adverse effects or with complaints at any time 
during the study are similar among the different classifi•
cations of arrhythmia. There is no evidence that those pa•
tients with arrhythmia who were receiving propranolol had 
a greater frequency of complaints or adverse effects than 
patients without arrhythmia. The propranolol-placebo com•
parisons are similar to those for the study group as a whole 
(1). 
Table 3 shows the frequency of use of nonstudy drugs 
during the trial. Antiarrhythmic drugs were prescribed more 
often for the placebo-treated than for the propranolol-treated 
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Table 3. Percent of Patients Taking Nonstudy Medication at any Time During the Trial for the Four Classifications of Arrhythmia 
VPBs > 0 
VPBs 2: IO/h or 
Runs or Multiform* VPBs 2: IO/h 
VPBs 2: IO/h Plus 
Runs Plus Multiform 
Propranolol Placebo Propranolol 
Medication (n = 1,370) (n = 1,380) (n = 672) 
Diuretic drugs 41 7 44.6 45.7 
DIgitalis 28.5 28.2 33.5 
AntiarrhythmIc agents 21.0 27.3 25.0 
Nonstudy beta-blockers 17.5 22.8 17.0 
*Protocol definition. VPBs = ventricular premature beats. 
patients for all four classifications. Except for the patients 
meeting the most stringent classification of arrhythmia, non•
study beta-receptor blockers were also used more frequently 
in the placebo-treated group. There was also a trend toward 
increasing use of diuretic drugs, digitalis and antiarrhythmic 
agents with the more stringent classifications. 
Patient compliance to medication at the last completed 
study visit is shown in Table 4. Compliance in the patients 
receiving propranolol decreased as the severity of arrhyth•
mia increased. This is primarily because of an increase in 
the number of patients not taking any study medication and 
a decrease in the number receiving the full protocol dose. 
Discussion 
Propranolol and ventricular arrhythmia. Previous re•
ports (15-17) of trials of beta-blockers claimed a reduction 
in sudden cardiac death, though the definitions of sudden 
death in those studies included mortality within 24 hours of 
the onset of symptoms. In addition, a decrease in ambient 
ectopic rhythm after administration of beta-blockers had 
been reported (18,19). Ventricular arrhythmia had been shown 
(8,10,20) to be an independent risk factor for sudden death 
and total mortality. Therefore, at the initiation of the Beta•
Blocker Heart Attack Trial, it was postulated that much of 
any observed benefit would occur in those patients who had 
complex ventricular arrhythmias. 
Analyses of data from the patients participating in the 
Placebo Propranolol Placebo Propranolol Placebo 
(n = 666) (n = 224) (n = 211) (n = 122) (n = 112) 
48.7 52.7 50.7 62.3 54.5 
32.1 41 I 36.5 48.4 38.4 
33.0 38.4 48.3 45.1 52.7 
22.1 15.2 20.4 14.8 14.3 
Beta-Blocker Heart Attack Trial who had both baseline and 
6 week ambulatory electrocardiograms have confirmed the 
antiarrhythmic properties of propranolol (4). Among pa•
tients with ventricular arrhythmia (defined as ventricular 
premature beats 2: 10th and pairs or runs) at baseline, the 
prevalence of arrhythmia at 6 weeks was 53% in the pro•
pranolol-treated group as compared with 73% in the pla•
cebo-treated group. Among patients with no baseline ar•
rhythmia, the prevalence of arrhythmia at 6 weeks was 12% 
in the propranolol-treated group and 21 % in the placebo•
treated group. In the latter group, the overall prevalence of 
ventricular premature beats was higher at 6 weeks than at 
baseline. This increase was blunted in the propranolol-treated 
group (4). 
Mortality and effect of propranolol. The data pre•
sented here do not support the hypothesis that reduction in 
mortality due to propranolol is primarily restricted to those 
patients with ventricular arrhythmia at baseline. When the 
protocol-specified classification of arrhythmia is examined, 
the relative benefit of propranolol is similar, regardless of 
whether the patient had the arrhythmia. This holds for all•
cause mortality, as well as coronary heart disease mortality 
and sudden cardiac death. These results are similar for two 
of the other three arrhythmia classifications (ventricular pre•
mature beats> ° and 2: lO/h). 
The presence of complex ventricular premature beats did 
identify a group of patients at approximately twice the risk 
of death as those without complex ventricular premature 
beats, though similar relative benefit from propranolol was 
Table 4. Percent of Patients Taking Study Medication at the Last Completed Study Visit for the Four Subgroups of Patients 
VPBs 2: IO/h or VPBs 2: 10/h Plus 
VPBs > 0 Runs or Multiform* VPBs 2: IO/h Runs Plus Multiform 
Compliance Measure Propranolol Placebo Propranolol Placebo Propranolol Placebo Propranolol Placebo 
No study medication 25.7 244 262 26.7 31 8 25.7 34.2 25.0 
Any study medication 74.3 75.6 738 733 68.2 74.3 65.8 75.0 
Full dose 61.0 694 60.9 66.6 52.3 66.4 49.1 65.7 
On nonstudy beta-blocker 8.7 12.0 8.6 132 7.3 II 8 5.8 6.5 
Any beta-blocker 83.0 120 82.4 13.2 75.5 11.8 716 6.5 
*Protocol definition. All abbreviation, as in Table 2 
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observed. Therefore, for the ~ame number of patients treated, 
the high-risk group will have a greater absolute benelit from 
the drug (that is, more lives saved per number treated). 
Interestingly, little or no benefit from propranolol is found 
in those patients with the classification of arrhythmia re•
quiring the most stringent criteria (ventricular premature 
beats ~ I ° plus pairs or runs plus multiform ventricular 
premature beats). This contrasts with the benefit noted in 
those without this arrhythmia. This might be a chance ob•
servation, enhanced by the relatively small number of pa•
tients and events in the arrhythmia subgroup. Another ex•
planation is that the requirement for having frequent ventricular 
premature beats and pairs or run~ and multiform ventricular 
premature beats identifies patients not only at high risk of 
mortality, but also at high risk of being harmed by taking 
beta-blockers. Beta-blockers, as well as other antiar•
rhythmic receptors, have at times been shown to be proar•
rhythmic (21). Thus, any benefit from the drug might be 
offset by toxicity. The use of diuretic drugs, digitali~ and 
antiarrhythmic agent~ was highest in this patient subgroup. 
These drugs may have played a role in minimizing the 
potential benefit from propranolol. It is also true that com•
pliance to study medication was not as good in this subgroup 
of patients, possibly impairing the ability to detect benefit. 
if any, from propranolol. 
Postulated mechanisms of propranolol's beneficial ef•
fect. The observation that patients without arrhythmia ben•
efited relatively as much from propranolol as those with 
arrhythmia, regardless of the c1a~sification. implies that there 
are mechanisms of action other than the reduction in ven•
tricular ectopic rhythm. Propranolol has been shown (22.23) 
to increase the threshold for ventricular fibrillation. Thl~ 
effect may be distinct from its observed effect on ventricular 
premature beats. There appears to be an association, how•
ever. between the presence of ventricular premature beat~ 
and the risk of fibrillation and sudden death (10.20,24,25). 
although it is uncertain whether the association i~ greater 
than with nonsudden cardiac death (9, II ,26). If the antl•
fibriIlatory action were primary. one might have expected 
more benefit in patients with arrhythmia. The benefit from 
propranolol might relate to an anti-ischemic effect, either 
directly (27) or through suppression of ventricular arrhyth•
mia (28). Propranolol may also operate by blocking beta2-
receptors, and thus, arrhythmia mediated through cate•
cholamine-induced hypokalemia (29). Whether the negative 
inotropic effect of propranolol or its bradycardic and hy•
potensive actions affected mortality is unknown. 
As previously reported (30). using baseline clinical cri•
teria (exclusive of ambulatory electrocardiogram) ascer•
tained in the acute phase of the myocardial infarction, the 
patients participating in the Beta-Blocker Heart Attack Trial 
were retrospectively divided into four subgroups: those with 
electrical problems, those with mechanical or pump prob-
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lem~, tho~e with both and those with neither. The three 
~ubgroupi> with electncal or mechanical disturbance~, or 
both. appeared to benefit from propranolol therapy, showing 
reduced mortality. Limited benefit from thc drug was found 
in the subgroup without such problems. Thus, patients who 
experienced electrical disturbances (ventricular fibrillation, 
ventricular tachycardia. atrioventricular [A Vj block or atrial 
fibnllation) before enrollment in the Beta-Blocker Heart 
Attack Trial ~eemed to benefit more from propranolol than 
tho~e without electrical disturbances. This differs from the 
finding that patient~ with ventricular arrhythmias on an am•
bulatory electrocardiogram recorded an average of 2 weeks 
after hospital admission did no better while taking propran•
olol. relative to placebo. than patients without such arrhyth•
mia~. The reason for this di~crepancy may be that the clinical 
as~eSf>ment relied on finding~ early in the course of the 
infarction. while the ambulatory electrocardiogram was per•
tormed in the convalescent phase. It has been reported that 
arrhythmia~. particularly ventricular fibrillation, occurring 
in the first few days of a myocardial infarction have little 
or no independent association with subsequent arrhythmias 
or mortality 01-35). although thi~ finding has been ques•
tioned (25.36). In addition. the difference in the Beta-Blocker 
Heart Attack Trial rei>ults may reHect the fact that the am•
bulatory electrocardiogram record!> episodes in one 24 hour 
period, wherea~ clinical findings occur over several days. 
Summary. The hypothe5is that propranolol would be of 
speCial benefit in patients with prior myocardial infarction 
who have ventncular anhythmia was not supported. The 
presence of arrhythmia on an ambulatory electrocardiogram, 
however, can Identify high-risk patienb. Because the per•
cent mortality i~ higher in ;,uch patlcnts. the !>imilar relative 
benefit lead~ to a greater absolute benefit in those receiving 
propranolol. With more lives ~aved per number treated. The 
mechanism of action by which propranolol reduces mortality 
i~ probably not solely an antiarrhythmic one. 
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